At 16 weeks, 70 percent of patients with moderate-to-severe atopic dermatitis receiving the investigational IL-13 inhibitor lebrikizumab combined with standard-of-care topical corticosteroids (TCS) achieved at least 75 percent improvement in overall disease severity (EASI-75*) in the ADhere trial, Eli Lilly and Company announced April 11 at the 4th Annual Revolutionizing Atopic Dermatitis Conference.